Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma research hub

An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).

Certain blood cancers can weaken your immune system, leaving you at higher risk of serious infections. This study tests whether an antibody drip called Gamunex-C, given alongside your usual medical care, can safely prevent severe bacterial infections and keep you out of hospital.